vestibulopathy in patients treated with CDDP or CBDCA
Conditions
Interventions
vHIT and SVV before administration of CDDP or CBDCA, each kur and one month after chemotherapy
Sponsors
Kyoto Prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) hospitalization or visits from approval to 28 December 2020 2) capable of obtaining informed consent with free will 3) age: 20 and more than 20, less than 90 4) male and female 5) patients in hospital who will be treated with CDDP or CBDCA. Observation will be continued until one month after chemotherapy (also after discharge)
Exclusion criteria
Exclusion criteria: 1) history of vertigo 2) history of lumbar vertebra disease 3) ear involvement of irradiation site 4) case in which first dose is less than normal dose due to original renal dysfunction 5) inappropriate case
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of VOR gain of vHIT and SVV depending on chemotherapy | — |
Countries
Japan
Contacts
Public ContactMasakatsu Taki
Kyoto Prefectural University of Medicine Department of of Otolaryngology - Head Neck Surgery
Outcome results
None listed